SpyGlass Pharma Q2 FY26 net loss widens to $19.9 million; R&D expenses rise to $10.9 million
SGP•Clinical program updates
- Phase 3 BIM-IOL enrollment remains on track for completion in 2027; BIM-DRS first-in-human trial still slated for H2 2026.
Cash balance and funding outlook
- Cash, cash equivalents and short-term investments totaled USD 234.2 million at June 30; funding expected to last through 2028.
Q2 net loss widens as expenses rise
- SpyGlass Pharma posted a Q2 net loss of USD 19.9 million, or USD 0.59 per share, versus a loss of USD 8.7 million a year earlier.
- R&D expense climbed to USD 10.9 million from USD 7.3 million, due to the hiring of clinical personnel.
- G&A expense rose to USD 11 million from USD 2 million, on higher professional service fees and personnel costs.
